3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Sezary Syndrome
3
Mycosis Fungoides
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Rectal Neoplasms
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
26
Nivolumab
10
Cisplatin
9
Gemcitabine
8
Docetaxel
6
enfortumab vedotin
5
atezolizumab
5
Ipilimumab
5
Carboplatin
5
sacituzumab govitecan
4
Paclitaxel
4
Pemetrexed
3
Cyclophosphamide
3
vofatamab
2
tremelimumab
2
tislelizumab
2
regorafenib
2
lenvatinib
2
epacadostat
2
durvalumab
2
avelumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Biopsy
2
Bevacizumab
2
B701 protein, Human herpesvirus 6
2
ALT-803
2
yeast-CEA vaccine
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Transitional Cell
×
Immunoglobulin G
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled